M&A

News

Asahi Kasei buys antiviral firm Aicuris for €780m

Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

News

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

Hims & Hers buys Australian digital health firm for $1.15bn

Hims & Hers, facing a threat to its compounded medicines business, has ramped up its push for international expansion by buying Eucalyptus Health.

News

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

News

Digital musculoskeletal care firm Sword buys rival Kaia

US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it for expansion in Europe.

Asahi Kasei buys antiviral firm Aicuris for €780m

GSK grows pipeline with 35Pharma takeover, Frontier deal

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Hims & Hers buys Australian digital health firm for $1.15bn

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

Digital musculoskeletal care firm Sword buys rival Kaia

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

M&A

Editor's Picks